Form 4: Guardant Health Co-CEO Sells $17.8M in Stock

Guardant Health's Co-Chief Executive Officer, Helmy Eltoukhy, sold 300,000 shares of common stock for approximately $17.8 million through a pre-planned trading arrangement.

Summary

• Helmy Eltoukhy, Co-Chief Executive Officer and Director of Guardant Health, Inc. (GH), sold a total of 300,000 shares of common stock on September 9, 2025.
• The sales were executed in two tranches: 294,723 shares at a weighted average price of $59.4447 per share, and 5,277 shares at a weighted average price of $59.9346 per share.
• The total value of the shares sold is approximately $17,836,200.
• Following these transactions, Eltoukhy beneficially owns 2,123,499 shares of Guardant Health common stock.
• The transactions were conducted pursuant to a Rule 10b5-1(c) trading plan, indicating a pre-scheduled sale.

Sentiment

Score: 4

Explanation: The sale of a significant number of shares by a Co-CEO is generally a negative signal. However, the fact that it was conducted under a Rule 10b5-1 plan mitigates some of the negative sentiment, as it suggests a pre-planned transaction for personal financial management rather than a reaction to adverse company-specific news.

Positives

• The sale was conducted under a Rule 10b5-1(c) plan, suggesting it was pre-scheduled and not necessarily indicative of a change in management's outlook on the company's immediate prospects.

Negatives

• A significant insider sale by a Co-Chief Executive Officer and Director could be perceived negatively by investors, potentially signaling a lack of confidence or a belief that the stock price is at a favorable level for selling.
• The sale represents a substantial divestment of approximately $17.8 million in common stock.

Risks

• Investor perception risk: Large insider sales, even if pre-planned, can sometimes lead to negative market sentiment or speculation about the company's future performance.

Future Outlook

NA

Industry Context

This filing is a standard insider transaction report and does not provide specific details to analyze in the broader industry context. Insider sales are common for diversification or liquidity purposes, especially for long-tenured executives.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a negative signal, potentially leading to a decrease in confidence or increased selling pressure on the stock. However, the 10b5-1 plan context may temper this reaction.
• Employees: No direct impact mentioned, but general market sentiment can indirectly affect employee morale or stock-based compensation value.

Key Dates

Recommendation

While a significant insider sale by a Co-CEO could be a 'sell' signal, the disclosure that the transaction was executed under a Rule 10b5-1 plan suggests it was a pre-scheduled event for personal financial planning, rather than a reaction to new, negative company information. This mitigates the immediate bearish interpretation. Investors should 'hold' and monitor future company performance and additional insider activity, as this single transaction, while large, does not necessarily indicate a fundamental shift in the company's prospects.

Keywords

Guardant Health, GH, Helmy Eltoukhy, Insider Sale, Form 4, SEC Filing, Stock Transaction, Co-CEO, Director, 10b5-1 Plan